An early mutation in KRAS has been implicated in the progression of pre-malignant pancreatic intra-epithelial neoplasia to invasive malignancy [18], and has also been demonstrated to play a vital role in tumour maintenance [20]. This evidence concerns the gene KRAS and neoplasm.